IMP 17307
Alternative Names: IMP-17307Latest Information Update: 31 Jan 2024
At a glance
- Originator IMPACT Therapeutics
- Developer Eikon Therapeutics; IMPACT Therapeutics
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer